Drug Treatments Archives - covid19.ecambiomed.com

Summary:
10 therapeutic agents are in active clinical trials. Another 15 therapeutic agents are in planning stages. Currently the three (3) most likely drugs to be safe and effective are, for critically ill COVID-19 patients: (1) Remdesivir anti-viral drug by Gilead, and (2) Actemra/RoActemra (Tocilizumab) immunosuppressive drug by Roche, and for early stage SARS-CoV-2 infection: (3) Avigan (favipiravir) anti-viral drug by Fujifilm, Japan.
Published for educational purposes and social benefit, not for profit. Not a recommendation or endorsement. Always consult your doctor for medical advice.

July 2021

CELL & HOST MICROBE | SnapShot: SARS-CoV-2 antibodies

sibiu1182021-07-17T08:35:03+00:00July 17th, 2021|

Monoclonal antibody therapies hold great promise for COVID-19; however, the recent emergence and spread of escape variants threaten to limit their value. Shown here are structural and linear representations of [...]

April 2021

OXFORD | PRINCIPLE | Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

sibiu1182021-04-13T00:57:41+00:00April 13th, 2021|

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in [...]

November 2020

KAROLINSKA INSTITUTET | Baricitinib treatment linked to reduced mortality in COVID-19 patients | JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

sibiu1182020-11-15T06:57:07+00:00November 15th, 2020|

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality ABSTRACT. Using AI we identified baricitinib as possessing anti-viral and anti-cytokine efficacy. We now show [...]

October 2020

CELL | Identification of required host factors for SARS-CoV-2 infection in human cells

sibiu1182020-10-25T07:38:32+00:00October 25th, 2020|

https://twitter.com/EricTopol/status/1320105387064918016?s=20 Highlights • Genome-wide CRISPR knockout screen identifies host factors for SARS-CoV-2 infection • Top-ranked genes include vacuolar ATPases, Retromer, Commander and Arp2/3 complex • Validation using CRISPR knockout, RNA [...]

BIO RENDER | COVID-19 Vaccine & Therapeutics Tracker [updated every Monday]

sibiu1182020-10-19T06:36:46+00:00October 19th, 2020|

Bio Render New addition counters are reset every Monday by 11:59 PM ET. Last updated October 17, 2020 at 11:12PM ET Reprinted for educational purposes and social benefit, not for [...]

August 2020

NATURE | Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

sibiu1182020-08-16T10:46:01+00:00August 16th, 2020|

Monoclonal antibodies (artist’s impression) are being harnessed against the coronavirus.Credit: Nanoclustering/Science Photo Library Monoclonal antibodies are complex and expensive to produce, meaning poor countries might be priced out. [...]

July 2020

SQUAWK BOX | Bill Gates | There could be a ‘substantial’ reduction in Covid-19 death rate by year’s end | Covid-19 testing is a ‘waste’ unless results are available within 48 hours

sibiu1182020-07-29T03:23:50+00:00July 29th, 2020|

Microsoft co-founder Bill Gates spoke with CNBC's Andrew Ross Sorkin about the coronavirus vaccine and treatment study results thus far and which efforts out there he thinks show the [...]

THE SCIENTIST | Seeking an Early COVID-19 Drug, Researchers Look to Interferons

sibiu1182020-07-25T23:56:52+00:00July 25th, 2020|

These antiviral proteins are produced by the body as a natural defense against viral infections and synthetic interferons might help prevent or treat the beginning stages of SARS-CoV-2 infection. By [...]

THE NEW YORK TIMES | New Treatment [interferon] for Covid-19 Shows Promise, but Scientists Urge Caution

sibiu1182020-07-25T23:58:56+00:00July 25th, 2020|

A small study of an inhaled form of a commonly available drug, interferon beta, suggests it could reduce the odds of patients becoming severely ill. By Benjamin Mueller July 20, [...]